Abstract
Binding assay is a common technique used to characterize ability of a ligand to interact with a specific biological target. A number of parameters, such as binding affinity, receptor density, and association/dissociation rate constants, can be measured by means of this technique. In most cases, implementation of the binding assay requires specific infrastructure for labeling and detecting the ligand, which impedes realization of this technique in a standard laboratory. Here we describe a simple fluorescence-based binding assay for angiotensin peptides and receptors, which does not require complex equipment and can be used for initial screening of the novel ligands or mutational studies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schiffrin EL (2002) Vascular and cardiac benefits of angiotensin receptor blockers. Am J Med 113(5):409–418
Ma TK, Kam KK, Yan BP, Lam YY (2010) Renin-angiotensin-aldosterone system blockade for cardiovascular diseases: current status. Br J Pharmacol 160(6):1273–1292. doi:10.1111/j.1476-5381.2010.00750.x
Bader M (2010) Tissue renin-angiotensin-aldosterone systems: targets for pharmacological therapy. Annu Rev Pharmacol Toxicol 50:439–465. doi:10.1146/annurev.pharmtox.010909.105610
Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor mas. Proc Natl Acad Sci U S A 100(14):8258–8263. doi:10.1073/pnas.1432869100
Fraga-Silva RA, Ferreira AJ, Dos Santos RA (2013) Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor pathway in hypertension. Curr Hypertens Rep 15(1):31–38. doi:10.1007/s11906-012-0324-1
Steckelings UM, Paulis L, Namsolleck P, Unger T (2012) AT2 receptor agonists: hypertension and beyond. Curr Opin Nephrol Hypertens 21(2):142–146. doi:10.1097/MNH.0b013e328350261b
Sridharan R, Zuber J, Connelly SM, Mathew E, Dumont ME (2014) Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim Biophys Acta 1838(1 Pt A):15–33. doi:10.1016/j.bbamem.2013.09.005
de Jong LA, Uges DR, Franke JP, Bischoff R (2005) Receptor-ligand binding assays: technologies and applications. J Chromatogr B Anal Technol Biomed Life Sci 829(1–2):1–25. doi:10.1016/j.jchromb.2005.10.002
Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA (2013) Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112(8):1104–1111. doi:10.1161/CIRCRESAHA.113.301077
Violin JD, DeWire SM, Yamashita D, Rominger DH, Nguyen L, Schiller K, Whalen EJ, Gowen M, Lark MW (2010) Selectively engaging beta-arrestins at the angiotensin II type 1 receptor reduces blood pressure and increases cardiac performance. J Pharmacol Exp Ther 335(3):572–579. doi:10.1124/jpet.110.173005
Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M (2004) Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 47(24):5995–6008. doi:10.1021/jm049715t
Slavik R, Herde AM, Bieri D, Weber M, Schibli R, Kramer SD, Ametamey SM, Mu L (2015) Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. Eur J Med Chem 92:554–564. doi:10.1016/j.ejmech.2015.01.028
Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136(Pt 7):2217–2227. doi:10.1093/brain/awt142
Auld DS, Farmen MW, Kahl SD, Kriauciunas A, McKnight KL, Montrose C, Weidner JR (2012) Receptor binding assays for HTS and drug discovery. In: Sittampalam GS, Coussens NP et al (eds) Assay guidance manual. Eli Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda, MD
Maguire JJ, Kuc RE, Davenport AP (2012) Radioligand binding assays and their analysis. In: Davenport AP (ed) Receptor binding techniques, vol 897, 3rd edn. Springer, New York, NY
Hulme EC, Trevethick MA (2010) Ligand binding assays at equilibrium: validation and interpretation. Br J Pharmacol 161(6):1219–1237. doi:10.1111/j.1476-5381.2009.00604.x
Kim TK, Eberwine JH (2010) Mammalian cell transfection: the present and the future. Anal Bioanal Chem 397(8):3173–3178. doi:10.1007/s00216-010-3821-6
Jankowski V, Tolle M, Santos RA, Gunthner T, Krause E, Beyermann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J (2011) Angioprotectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 25(9):2987–2995. doi:10.1096/fj.11-185470
Pinheiro SV, Simoes e Silva AC, Sampaio WO, de Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M, Santos RA (2004) Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor mas agonist in the mouse kidney. Hypertension 44(4):490–496. doi:10.1161/01.HYP.0000141438.64887.42
Savergnini SQ, Beiman M, Lautner RQ, de Paula-Carvalho V, Allahdadi K, Pessoa DC, Costa-Fraga FP, Fraga-Silva RA, Cojocaru G, Cohen Y, Bader M, de Almeida AP, Rotman G, Santos RA (2010) Vascular relaxation, antihypertensive effect, and cardioprotection of a novel peptide agonist of the MAS receptor. Hypertension 56(1):112–120. doi:10.1161/HYPERTENSIONAHA.110.152942
Fraga-Silva RA, Pinheiro SV, Goncalves AC, Alenina N, Bader M, Santos RA (2008) The antithrombotic effect of angiotensin-(1–7) involves mas-mediated NO release from platelets. Mol Med 14(1–2):28–35. doi:10.2119/2007-00073.Fraga-Silva
Leal MC, Pinheiro SV, Ferreira AJ, Santos RA, Bordoni LS, Alenina N, Bader M, Franca LR (2009) The role of angiotensin-(1–7) receptor mas in spermatogenesis in mice and rats. J Anat 214(5):736–743. doi:10.1111/j.1469-7580.2009.01058.x
Santos RA, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor MAS knockout mice. Hypertension 47(5):996–1002. doi:10.1161/01.HYP.0000215289.51180.5c
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Bragina, M.E., Stergiopulos, N., Fraga-Silva, R.A. (2017). Fluorescence-Based Binding Assay for Screening Ligands of Angiotensin Receptors. In: Thatcher, S. (eds) The Renin-Angiotensin-Aldosterone System. Methods in Molecular Biology, vol 1614. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7030-8_13
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7030-8_13
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7028-5
Online ISBN: 978-1-4939-7030-8
eBook Packages: Springer Protocols